

Supplementary Fig. S6. Detection of short variant gene alterations using the FACT next generation sequencing assay on ctDNA samples from patients dosed at 1400 mg dose (n=23). Number and type of short variant gene alterations in individual patients (A) and overall (B) in baseline samples. Gene alterations were defined as mutations to have known or likely impact on protein function; 19 of 23 patients dosed at 1400 mg had at least one detectable gene alteration. (C) Prevalence of mutated genes in baseline, Cycle 3 Day 1 (C3D1) and end-of-treatment samples with best overall response.

